Dosimetry of a new P-32 ophthalmic applicator.

PURPOSE: The potential of P-32 ophthalmic applicator irradiation after pterygium excision has been demonstrated as an alternative to Sr∕Y-90 irradiation. This study aimed to provide the clinical dosimetry for this new applicator. METHODS: The prototype of a cylindrical P-32 applicator was fabricated according to the Monte Carlo (MC)-based design study. At a nominal activity of 6 mCi (0.22 GBq), the absorbed dose rate at the front surface (i.e., reference dose rate) was measured by using an extrapolation ionization chamber (EC). The radiochromic film (RCF) was also used to measure the reference dose, axial depth dose distributions and transaxial dose profiles at various depths in water. RESULTS: The reference dose rate was 3.89 ± 0.14 cGy∕s for EC and 3.84 ± 0.25 cGy∕s for RCF. The depth dose rate was reduced approximately by an order of magnitude for every 2 mm depth in water. Measured depth doses in depths of 0.5-2.5 mm agreed with Monte Carlo data within ±3%. Due to nonuniform absorption of P-32 into an absorbent disk, the dose profiles were not symmetric and decreased more rapidly toward the periphery than those predicted by the MC. The authors confirmed no leakage of P-32 activities and negligible exposure rate around the hand grip of the applicator. CONCLUSIONS: The P-32 applicator can deliver therapeutic doses to the surface of the conjunctiva, while sparing the lens better than Sr∕Y-90 applicators. The doses at any points from the P-32 applicator could be calculated by using the measured dosimetry data. They also confirmed no leakage of the source, reliable integrity of the applicator, and negligible exposure level around the hand grip of the applicator. However, due to a possibility of nonuniform distributions of P-32 in an absorbent disk, measuring dose profiles as well as the reference dose rate for every new applicator would be recommended.

Development of a high performance (188)W/(188)Re generator by using a synthetic alumina.

A synthetic alumina functionalized with a sulfate moiety has been developed as the column material of (99)Mo/(99m)Tc and (188)W/(188)Re generators. This material is synthesized by a sol-gel processing. In order to characterize the adsorbent for the (188)W/(188)Re separation, both batch and column contact experiments were conducted. As a result of the experiments, it is found that the maximum capacity of the adsorbent for tungsten is higher than 450mg/g. Hence it is possible to produce approximately 3Ci (188)W/(188)Re generator with only 1g of the adsorbent from (188)W solutions supplied from ORNL, USA or RIAR, Russia. A demonstration study was conducted to show the performance of an (188)W/(188)Re generator column. In this study, 1Ci of (188)W purchased from RIAR, Russia, is loaded on a 0.9cm ID column packed with 0.7g of the adsorbent. Elution of (188)Re is performed every 4-7 days by using the saline solution for more than three months. Nearly 100% of tungsten is loaded by passing 5ml of the (188)W solution (pH=8) through the dry packed column at a 1ml/min flow rate. Elution efficiency of (188)Re is 70-90% by using 5ml of the saline solution. The ratio of (188)W/(188)Re in the eluted solution is 0.002-0.003%. When a Sep-Pak containing 0.26g of acid alumina is installed as a tandem column, the ratio is decreased to less than 10(-3)%. Thin layer chromatography for the eluted (188)Re solution shows 100% radiochemical purity. Also, alumina content in the eluted solution shows less than 10ppm. Through this study, the performance of this adsorbent was successfully demonstrated. By using the developed adsorbent, minimization of the generator column and consequently the volume of eluant could be possible while maintaining the quality of (188)Re just as much as that available in the market.

One column operation for (90)Sr/(90)Y separation by using a functionalized-silica.

Organo-ceramic hybrid materials have been developed as the separation media for a (90)Sr/(90)Y generator system. Currently available (90)Y is generally extracted from a mother solution by a solvent extraction or a successive column operation. Both processes are successfully applied to produce (90)Y with a high quality standard. However, such processes are highly dependent on what kind of extracting materials are employed. Hence, some of the previously developed technologies are not adequate for a (90)Y production because of a waste generation or leaching of radiolytic end-products from the extracting materials. In this study, high performance organo-ceramic hybrid materials have been applied for the extraction of (90)Y. The hybrid materials have properties of both a ceramic and a solvent extractant by molecularly implanting the extracting molecules on to the ceramic surfaces. In this study, organo-phosphorus functionalized hybrid materials are synthesized and tested as the separation media for the (90)Y/(90)Sr generator system. An adsorptive extraction with a small Sep-Pak type column can recover more than 92% of (90)Y with a contamination ratio of (90)Sr/(90)Y=1.2x10(-5) from the mother solution and 70% with 5x10(-7).

Potential use of P-32 ophthalmic applicator: Monte Carlo simulations for design and dosimetry.

Postoperative beta-irradiation after pterygium excision has been considered a valuable therapeutic procedure to reduce the recurrence rate. Recently, it was reported that beta-irradiation also substantially reduced the risk of surgical failure after glaucoma surgery. Pure beta-irradiation using a 90Sr/Y applicator has been almost exclusively used for this purpose. As an alternative to 90Sr/Y beta-irradiation, we propose treatment with betas of a 32P source. While 32P has a lower maximum energy (1.71 MeV) than 90Sr/Y (2.27 MeV), it has an average energy comparable to that of 90Sr/Y. Furthermore, it can be produced easily in a nuclear reactor by neutron activation and is considered a less hazardous material. Monte Carlo simulations for the dosimetry of proposed 32P applicators were performed using the MCNP5 code. The structure and dimension of the 32P applicators were based on those of the 90Sr/Y applicators currently available, while medical plastic encapsulation and liquid source were chosen to enhance beta-dose to the surface of the conjunctiva. The 32P applicator showed that the surface dose distribution (up to 0.75 mm depth) is very similar to that of 90Sr/Y. However, beyond 0.75 mm depth, the 32P doses decrease with depths more rapidly than 90Sr/Y doses. In order to achieve the same surface dose rate, the required 32P activity is about three times that for a 90Sr/Y applicator. We conclude that the proposed 32P applicator can deliver therapeutic doses to the target lesion while sparing the lens better than the 90Sr/Y applicator. The 32P activity required to deliver therapeutic doses can be produced in a 30 MW reactor available at the Korea Atomic Energy Research Institute.

Gene cloning, sequencing, and expression of an esterase from Acinetobacter lwoffii I6C-1.

The esterase-encoding gene, estA, was cloned from Acinetobacter lwoffii I6C-1 genomic DNA into Escherichia coli BL21(DE3) with plasmid vector pET-22b (pEM1). pEM1 has a 4.4-kb EcoRI insert that contained the complete estA gene. A 2.4-kb AvaI- SphI DNA fragment was subcloned (pEM3) and sequenced. estA gene encodes a protein of 366 amino acids (40,687 Da) with a pI of 9.17. The EstA signal peptide was 31 amino acids long, and the mature esterase sequence is 335 amino acids long (37.5 kDa). The conserved catalytic serine residue of EstA is in position 210. The EstA sequence was similar to that of the carboxylesterase from Acinetobacter calcoaceticus (75% identity, 85% similarity), Archaeoglobus fulgidus (37% identity, 59% similarity), and Mycobacterium tuberculosis (35% identity, 51% similarity). These enzymes contained the conserved motif G-X(1)-S-X(2)-G carrying the active-site serine of hydrolytic enzyme. The EstA activity in A. lwoffii I6C-1 remains constant throughout the stationary phase, and the activity in E. coil BL21 (DE3) with pEM1 was similar to A. lwoffii I6C-1.